- Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory disease affecting the axial skeleton, primarily managed through anti-inflammatory and biologic therapies. These approaches focus on reducing disease activity, alleviating symptoms, and improving functional ability
- The growing recognition of nr-axSpA as a distinct clinical entity, supported by improved MRI diagnostics and global clinical guidelines, is fueling demand for effective therapeutic solutions. The rise in rheumatology referrals and updated ASAS criteria are contributing to increased patient identification
- North America is expected to dominate the nr-axSpA therapeutics market with a share of 38.6%, attributed to advanced biologics availability, high screening rates, and an established specialist network
- Asia-Pacific is expected to be the fastest growing region in the nr-axSpA therapeutics market during the forecast period due to the expansion of healthcare access, rising awareness of early inflammatory arthritis, and growing use of biosimilars
- IL-17 inhibitors are expected to dominate the market with a market share of 45.3% due to their favorable clinical profile, high patient satisfaction scores, and recommendation in updated treatment guidelines. Despite the emergence of biosimilars and newer agents, IL-17 inhibitors maintain their position as first-line biologics in many practices, offering durable disease control, particularly in HLA-B27-positive populations
